News and Announcements
Actinogens’ Xanamem™ to Showcase Cortisol Hypothesis
- Published June 30, 2016 10:08AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29th Sydney 2016, ASX Announcement
Actinogen Medical (ASX:ACW) is pleased to announce the key data supporting its novel Alzheimer’s drug Xanamem™, has been selected by an independent expert panel for presentation at the world’s largest dementia research conference – the Alzheimer’s Association International conference (AAIC), in Toronto 22nd – 28th July, 2016.
The presentation entitled, “Xanamem™ a novel 188-HSD1 inhibitor with as potential to provide durable symptomatic and disease modifying benefits in Alzheimer’s disease“, will include results on Xanamem™’s succesful Phase I human trials and importantly confirm that following oral administration Xanamem™’s effectively crosses the blood-brain-barrier and gets to the brain, its primary site of action in Alzheimer’s disease.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
